OncRef

Clinical Trial: NCT05534438

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

Status:

RECRUITING

Phase:

Phase 2

Lead Sponsor:Memorial Sloan Kettering Cancer Center
Information Provided By:Memorial Sloan Kettering Cancer Center
Last Update Posted:2026-10-02

Study Overview

Brief Summary

The purpose of this study is to see if using Stereotactic Body Radiation Therapy/SBRT to treat a single metastatic site where cancer has worsened may be an effective treatment for people with oligometastatic breast cancer. Participants will stay on their usual drug therapy while they receive SBRT. This combination of SBRT to a single metastatic site and usual drug therapy may prevent participants' cancer from worsening in other metastatic sites or spreading.

Official Title

Stereotactic Body Radiation Therapy (SBRT) to Extend the Benefit of Systemic Therapy in Patients With Solitary Disease Progression

Conditions

Oligometastatic Breast Carcinoma, Breast Cancer, Metastatic Breast Cancer, Metastatic Breast Carcinoma, ER+ Breast Cancer, HER2+ Breast Cancer

Intervention / Treatment

  • Radiation: Stereotactic body radiotherapy

Other Study ID Numbers

  • 22-259

Start Date (Actual)

2022-09-06

Primary Completion Date (Estimated)

2027-09-06

Study Completion Date (Estimated)

2027-09-06

Enrollment (Estimated)

46

Study Type

Interventional

Phase

Phase 2